Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TGIF1-silenced adipose-derived stem cell exosomes
- Development stage
- Preclinical
- Lead developer
- Shanghai Tenth People's Hospital
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Injection
01
Overview
TGIF1-silenced adipose-derived stem cell exosomes are an experimental exosome-based therapy developed by researchers at Shanghai Tenth People's Hospital. These exosomes are harvested from adipose-derived mesenchymal stem cells (ADSCs) in which the TGFB-induced factor homeobox 1 (TGIF1) gene has been silenced, typically using RNA interference techniques such as shRNA. TGIF1 is a transcriptional corepressor that negatively regulates the TGF-beta/Smad signaling pathway. By silencing TGIF1 in the parent stem cells, the resulting exosomes are enriched with a specific cargo of microRNAs and proteins that enhance tenogenic differentiation and collagen synthesis while potentially reducing peritendinous adhesion and fibrosis. This therapy is primarily investigated for the treatment of musculoskeletal conditions, including rotator cuff injuries, cruciate ligament tears, and various forms of tendinitis, with the goal of improving the quality of tendon-to-bone healing and functional recovery.
- Other names
- TGIF1-silenced ADSC exosomesTGIF-1-silenced ADSC exosomesTGIF 1-silenced ADSC exosomesTGIF1-silenced adipose-derived mesenchymal stem cell exosomesTGIF-1-silenced adipose-derived mesenchymal stem cell exosomesTGIF 1-silenced adipose-derived mesenchymal stem cell exosomesTGIF1-silenced ADMSC-ExosTGIF-1-silenced ADMSC-ExosTGIF 1-silenced ADMSC-Exos
Beyond the preview
Go deeper on TGIF1-silenced adipose-derived stem cell exosomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TGIF1-silenced adipose-derived stem cell exosomes.